



**Name:** Thorsten Simon, Prof. Dr.

**Profession:** pediatrician, neonatologist and pediatric hematologist/oncologist

**Highest degree:** Dr. med. 1991, Habilitation 2006

**Short description:** Thorsten Simon is a pediatrician, neonatologist and pediatric hematologist/oncologist. He began his training in pediatric oncology and hematology at the University Hospital of Cologne in 1997 and became head of the Department of Pediatric Oncology and Hematology in 2013. Thorsten Simon is currently the coordinators for the neuroblastoma group of the Society for Pediatric Hematology and Oncology (GPOH) and the national representative for Germany in SIOPEN. He is principal investigator of the NB 2016 neuroblastoma registry of the GPOH and principal investigator of the NB 2015 LR clinical trial for low-intermediate risk patients, which is expected to start enrolling patients in 2025. Thorsten Simon is a member of the SIOPEN Executive Committee, the SIOPEN Clinical Trials Committee and a member of several study committees. Most of Thorsten Simon's publications can be found at <https://orcid.org/0000-0002-3425-8451>. Thorsten Simon's current H-index is 38.

**Affiliation:** University of Cologne, Department of Pediatric Oncology and Hematology

**Brief description of the organization:** The University Hospital of Cologne has more than 11,000 employees and treats approx. 60,000 inpatients and approx. 300,000 outpatients every year. Together with the university hospitals in Aachen, Bonn and Düsseldorf, the University Hospital Cologne is part of the *Center for Integrated Oncology* (CIO ABCD) and, together with the University Hospital Essen, forms the cancer center *NCT Cologne Essen*. The Department of Pediatric Oncology/Hematology at the University Hospital Cologne is ranked among the 20 largest pediatric oncology/hematology centers in Germany. Located in one of the most densely populated regions in Germany, it provides care for a population of around 4 million people. The department has been certified according to the criteria of the German Cancer Society since 2016 and according to the criteria of JACIE since 2019. The Department of Pediatric Oncology/Hematology is embedded in the regional research network of the West German Pediatric Study Center (<https://www.wpsz.de/>), in the clinical study landscape of the Society for Pediatric Oncology and Hematology (GPOH) and in the European neuroblastoma trials group SIOPEN (<https://www.siopen.net/>). The scientific focus of the department is on neuroblastoma studies and early clinical trials in solid tumors. The clinical scientific activities are closely linked to the work of the Department of Experimental Pediatric Oncology at the site, which is headed by Prof. Dr. Fischer.